CASIF CASI Pharmaceuticals, Inc. Annual reports only
Pharmaceutical Preparations · OTC · SEC CIK 1962738 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-15.8%
TTM net income YoY-45.6%
TTM EPS YoY-26.7%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin39.1%
Operating margin-138.8%
Net margin-137.6%
FCF margin-103.2%
EBITDA margin-134.3%
Returns
ROE-301.8%
ROA-60.9%
ROIC (approx.)-435.9%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets96.6%
Debt / equity0.00x
Current ratio1.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $20.71M | $28.54M | $33.88M | $43.11M | $30.17M |
| Cost of revenue | $10.64M | $17.39M | $13.83M | $15.83M | $12.56M |
| Gross profit | $10.08M | $11.15M | $20.05M | $27.28M | $17.61M |
| R&D expense | $6.31M | $8.92M | $9.86M | $16.00M | $14.42M |
| SG&A expense | $28.27M | $23.58M | $25.39M | $23.45M | $23.70M |
| Operating income | -$45.01M | -$39.62M | -$25.08M | -$34.03M | -$41.52M |
| Interest expense | — | — | — | $0 | $2,900 |
| Pretax income | -$45.87M | -$38.07M | -$26.29M | -$37.43M | -$35.84M |
| Income tax | — | $0 | -$81,000 | $1.98M | $0 |
| Net income | -$48.06M | -$39.26M | -$26.96M | -$41.01M | -$36.65M |
| EBITDA | -$43.81M | -$38.32M | -$22.58M | -$32.83M | -$41.02M |
| EPS (basic) | -2.59 | -2.56 | -2.02 | -3.01 | -2.69 |
| EPS (diluted) | -2.59 | -2.56 | -2.02 | -3.01 | -2.69 |
| Weighted avg. shares (diluted) | 18.54M | 15.34M | 13.36M | 13.65M | 13.61M |
| Banking | |||||
| Net interest income | — | — | $614,000 | $127,000 | $321,000 |
| Balance sheet | |||||
| Cash & equivalents | $5.63M | $13.47M | $17.08M | $47.11M | $38.70M |
| Short-term investments | — | — | $12.01M | $1.46M | $9.87M |
| Receivables | $4.09M | $15.35M | $9.55M | $12.97M | $9.80M |
| Inventory | $1.60M | $5.25M | $15.88M | $6.14M | $1.91M |
| Current assets | $13.46M | $39.58M | $59.34M | $73.42M | $61.97M |
| PP&E, net | $6.97M | $7.87M | $9.24M | $11.83M | $12.71M |
| Intangibles | $221,000 | $238,000 | $1.84M | $1.06M | $12.20M |
| Total assets | $25.65M | $53.67M | $75.27M | $96.23M | $138.30M |
| Current liabilities | $49.67M | $36.45M | $16.73M | $17.00M | $13.19M |
| Short-term debt | $19.19M | $18.39M | — | — | — |
| Long-term debt | — | — | $18.89M | — | — |
| Total debt | — | — | $18.89M | — | — |
| Total liabilities | $62.93M | $51.82M | $51.10M | $29.30M | $30.34M |
| Shareholders' equity | -$37.28M | $1.85M | $24.16M | $44.57M | $84.50M |
| Net debt | — | — | $1.81M | — | — |
| Shares outstanding | 20.56M | 15.49M | 13.38M | 13.46M | 13.98M |
| Cash flow statement | |||||
| Operating cash flow | -$20.75M | -$29.22M | -$19.97M | -$21.09M | -$26.84M |
| Capital expenditure | $16,000 | $223,000 | $204,000 | $5.61M | $8.95M |
| Free cash flow | -$20.77M | -$29.45M | -$20.17M | -$26.70M | -$35.79M |
| Investing cash flow | $951,000 | $11.24M | -$9.67M | $31.16M | -$20.69M |
| Financing cash flow | $11.25M | $15.43M | -$907,000 | -$3.27M | $29.64M |
| Depreciation & amortization | $1.20M | $1.30M | $2.50M | $1.20M | $500,000 |
| Stock-based compensation | $2.99M | $1.31M | $7.22M | $7.01M | $7.77M |
| Share buybacks | — | — | $278,000 | $3.27M | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.